Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer

Pancreatic cancer is the fourth leading cause of death worldwide due to its poorest prognoses with a 7% 5-year survival rate. Eighty percent of pancreatic cancer patients relapse after chemotherapy and develop early metastasis and drug resistance. Resistance to nucleoside analog gemcitabine frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Lung-Hung, Hsu, Kai-Wen, Chiang, Cheng-Ming, Yang, Hsiu-Ju, Liu, Yu-Huei, Yang, Shun-Fa, Peng, Pei-Hua, Cheng, Wei-Chung, Wu, Heng-Hsiung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576602/
https://www.ncbi.nlm.nih.gov/pubmed/33082357
http://dx.doi.org/10.1038/s41598-020-73659-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576602/
https://www.ncbi.nlm.nih.gov/pubmed/33082357
http://dx.doi.org/10.1038/s41598-020-73659-z

Ejemplares similares